Opus Genetics (IRD) Operating Leases (2019 - 2020)
Opus Genetics (IRD) reported Operating Leases of $25790.0 for Q1 2020, down 85.79% year-over-year from $181490.0 in Q2 2019, and down 59.45% on a QoQ basis from $63605.0 in Q4 2019.
Opus Genetics (IRD) has 2 years of Operating Leases data on file, last reported at $25790.0 in Q1 2020.
- Quarterly Operating Leases fell 85.79% year-over-year to $25790.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $25790.0 (down 85.79% YoY) and the FY2019 annual result came in at $63605.0, changed N/A from the prior year.
- Operating Leases slipped to $25790.0 in Q1 2020 per IRD's latest filing, from $63605.0 in the prior quarter.
- Across five years, Operating Leases topped out at $181490.0 in Q1 2019 and bottomed at $25790.0 in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 25,790.00 |
| Dec 31, 2019 | 63,605.00 |
| Sep 30, 2019 | 100,397.00 |
| Jun 30, 2019 | 136,196.00 |
| Mar 31, 2019 | 181,490.00 |